Veru Inc Q2 Net Loss Shrinks to $3.1M, Stock Rises 3.5%
VERU•Veru Inc reduced its Q2 FY2026 net loss from $7.9M to $3.1M while cutting operating expenses, and reported pre-market stock gains of 3.52% to $2.35. The company projects EPS losses of $0.44 for Q3 and $0.49 for Q4 FY2026 and highlights progress in its enobosarm obesity treatment trials.
1. Q2 FY2026 Financial Results
Veru Inc reported a net loss from continuing operations of $3.1 million in Q2 FY2026, down from a $7.9 million loss in the year-ago period. This improvement reflects tighter cost controls and lower operating expenses as the company focuses on its core development programs.
2. Future EPS Guidance
Management projects a loss per share of $0.44 for Q3 FY2026 and $0.49 for Q4 FY2026, maintaining a negative earnings trajectory while investing in clinical trials. These forecasts underscore ongoing funding needs and the importance of trial milestones for financial stability.
3. Enobosarm Clinical Development
Veru continues to advance enobosarm in its Phase IIb PLATEAU obesity trial, targeting tissue-selective fat loss combined with GLP-1 receptor agonists. Positive interim data could validate the treatment’s potential to preserve lean mass in older patients with sarcopenic obesity.
4. Market Reaction and Outlook
Shares climbed 3.52% in pre-market trading to $2.35, reflecting investor confidence in the reduced losses and clinical progress. With a market capitalization of $36.4 million, Veru’s performance signals resilience as it approaches key regulatory and trial readouts.
